Key Findings

• Rising numbers of young people with gender dysphoria are seeking medical treatment, yet professional opinions are deeply divided—US medical groups broadly support 'gender-affirming care' while several European countries are restricting medical interventions for minors due to insufficient evidence.
• Major US medical organizations describe gender-affirming treatments as 'evidence-based,' but independent experts found serious methodological flaws in their guidelines, including weak evidence paired with strong recommendations and failure to conduct proper systematic reviews of treatment outcomes.
• Systematic reviews by Sweden, Finland, the UK's NICE, and Florida's health agency all concluded that evidence for puberty blockers, hormones, and surgeries in minors is inconclusive, insufficient, or of very low quality—directly contradicting claims of scientific certainty.
• The number of young people discontinuing hormone treatment may be as high as 20-30% within a few years, and 'detransitioners' are increasingly speaking out about harms from early medical interventions that they say were not truly informed consent.
• Clinical practice has shifted rapidly toward faster medicalization, with some teens receiving hormones within 12 months of their first clinic visit and mental health evaluations being de-emphasized, raising concerns about inadequate assessment of whether gender dysphoria will persist.

Abstract

Background: The number of children and adolescents presenting with gender dysphoria has risen sharply in recent years, particularly among birth-registered females, fueling intense debate over the appropriateness and safety of medical and surgical interventions in minors. Objective: To examine the divergence between United States medical societies and several European health authorities regarding the evidence base for pediatric gender-affirming care, and to assess whether current treatment recommendations meet standards for evidence-based medicine. Methods: This investigative report synthesizes policy statements and clinical guidelines from major professional organizations—including the American Academy of Pediatrics (AAP), the World Professional Association for Transgender Health (WPATH), the Endocrine Society, and national health bodies in Sweden, Finland, and England—alongside published systematic reviews, GRADE evidence appraisals, and expert interviews. Results: While US medical groups broadly endorse puberty suppression, cross-sex hormones, and surgery for adolescents, European authorities have recently restricted medical intervention in minors, citing “insufficient and inconclusive” evidence. Systematic reviews commissioned by the Endocrine Society and WPATH found the quality of evidence supporting hormonal treatment in adolescents to be “low” or “very low,” yet guidelines often pair strong recommendations with weak evidence—a practice experts note violates standards for trustworthy guideline development. Long-term outcome data are sparse, detransition rates remain poorly quantified, and many studies suffer from short follow-up, high loss to follow-up, and lack of control groups. Meanwhile, clinical practice in the US has shifted toward rapid medicalization, with some patients receiving hormones within months of their first visit and reduced emphasis on mental health assessment. Conclusions: Despite claims of scientific consensus, high-quality evidence supporting medical transition in minors is lacking. The divergence between US and European approaches reflects unresolved uncertainty about long-term benefits and harms. Clinicians, policymakers, and families should recognize that current treatment recommendations rely heavily on expert opinion rather than robust evidence, underscoring the need for rigorous, long-term research and transparent informed consent.

Summary

This BMJ investigation examines the growing debate over medical treatment for gender dysphoria in young people, highlighting a sharp divide between US medical organizations that broadly support "gender-affirming care" (including puberty blockers, hormones, and surgery) and several European countries that have recently restricted such interventions due to insufficient evidence of safety and efficacy. The article critiques the weak evidence base underlying major treatment guidelines, with experts noting that systematic reviews have found the quality of evidence to be "low" or "very low," and that some guidelines inappropriately label consensus-based recommendations as "evidence-based."

Conclusion

This investigative report from The BMJ concludes that despite claims of consensus, gender-affirming medical treatments for minors with gender dysphoria lack strong evidence-based support. Key findings include: (1) US medical organizations (WPATH, AAP, Endocrine Society) endorse gender-affirming care including puberty blockers, hormones, and surgeries, while several European countries (Sweden, Finland, France, UK) have moved to restrict medical interventions for minors, prioritizing psychological care; (2) systematic reviews commissioned by guideline bodies found evidence quality to be "low" or "very low," with experts criticizing the misapplication of "evidence-based" labeling to recommendations not meeting rigorous standards; (3) the surge in treatment of minors—particularly birth-registered females with no prior history of gender dysphoria—has outpaced research, with long-term outcomes unknown and detransition rates potentially as high as 20-30%; (4) clinical practice has shifted toward rapid medicalization, with concerns about inadequate assessment and perfunctory informed consent processes; and (5) prominent evidence-based medicine experts conclude that when rigorous systematic reviews find "we don't know," claims of certainty are not evidence-based, and consensus-based guidelines should not be called evidence-based.